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Abstract:  Alcohol  dependence  is  correlated  with  a  wide  spectrum  of  medical, 
psychological, behavioral, and social problems. Acute alcohol abuse causes damage to and 
functional  impairment  of  several  organs  affecting  protein,  carbohydrate,  and  fat 
metabolism. Mitochondria participate with the conversion of acetaldehyde into acetate and 
the generation of increased amounts of NADH. Prenatal exposure to ethanol during fetal 
development induces a wide spectrum of adverse effects in offspring, such as neurologic 
abnormalities and pre- and post-natal growth retardation. Antioxidant effects have been 
described  due  to  that  alcoholic  beverages  contain  different  compounds,  such  as 
polyphenols  as  well  as  resveratrol.  This  review  analyzes diverse  topics  on  the  alcohol 
consumption effects in several human organs and demonstrates the direct participation of 
mitochondria as potential target of compounds that can be used to prevent therapies for 
alcohol abusers. 




Over the centuries, alcohol has become the most socially-accepted addictive drug worldwide [1]. 
Excessive alcohol use is the third leading cause of preventable death in the United States [2]. Although 
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normative alcohol use is ubiquitous, alcohol dependence is a serious medical illness [3], experienced 
by  ≈14%  of  alcohol  users  [4].  Alcohol  dependence  constitutes  a  substantial  health  and  economic 
burden,  costing  an  estimated  $184  billion  in  expenditures  stemming  from  alcohol-related  chronic 
diseases  such  as  heart  disease  [5],  Alzheimer’  s  disease  [6],  stroke  [7],  liver  disease  [8],  
cancer [9], chronic respiratory disease [10], diabetes mellitus [11] and bone disease [12], which may 
develop following chronic alcohol ingestion and contribute to the alcoholism-related high morbidity 
and  mortality.  Alcohol abuse may  also trigger a  cascade of acute  health problems  such  as  traffic  
accident-related injuries, social problem including domestic violence, loss of work-place productivity, 
economic burden on society, crime and public disorder [13]. 
Alcohol use is characterized by central nervous system (CNS) intoxication symptoms, impaired 
brain activity, poor motor coordination, and behavioral changes [14], largely as a result of impaired 
CNS  activity  due  to  alcohol’s  effect  on  synthesis  [15],  release  [16]  and  signaling  [17]  of 
neurotransmitters, including serotonin [18], glutamate [19], GABA [20], endocannabinoids [21] and 
their  receptors.  Alcohol  abuse  causes  functional  impairment  of  the  gastrointestinal  tract  [22],  
liver [23], and pancreas [24]. It also affects protein, carbohydrate, and fat metabolism [25], and leads 
to insufficient immune system responses to infections [26], impairs the ability of the host to counteract 
hemorrhagic shock [27], augments corticosteroid release [28], and delays wound healing [29], thus 
contributing to higher morbidity and mortality, and prolonged recovery from trauma [30]. 
Alcohol  intoxication  results as  a  tolerance  and  physical dependence.  Tolerance is  defined  as  a 
reduced response to a constant amount of ethanol or an increase in the amount necessary to elicit the 
same effect [31]. Dependence is characterized by a withdrawal syndrome upon cessation of ethanol 
exposure [31]. Although significant progress had been made in the area of alcohol research during the 
past several decades, the pathogenesis of alcohol use and abuse is not fully understood. Understanding 
the mechanism that leads to tolerance and dependence may give valuable insight into alcohol addiction 
and ultimately result in effective therapeutic intervention to combat this disorder [31].  
1.2. Alcohol Metabolism 
The effects of alcohol on various tissues depend on its concentration in the blood over time. After 
oral administration, ethanol is readily absorbed by the gastrointestinal tract; absorption takes place by 
passive diffusion through the stomach wall (about 20%), being the remaining 80% absorbed through 
the duodenum and small intestine wall [32]. Elimination of absorbed ethanol occurs primarily through 
metabolism (95–98%), with small fractions of the administered dose being excreted unchanged in the 
breath (0.7%), sweat (0.1%), and urine (0.3%) [33]. 
In adult nonalcoholic individuals, most ethanol metabolism occurs in the liver, mainly via oxidation 
catalyzed by alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), cytochrome P450 2E1 
(CYP2E1), and catalase [34,35] enzymes (Figure 1). In people who consume alcohol at moderate 
levels (or only occasionally), the ethanol (CH3CH2OH) is oxidized to acetaldehyde (CH3CHO), in a 
reversible reaction catalyzed by class I ADH in the cytosol of hepatocytes [36]. Due to high affinity 
(Km  =  0.05–0.1  g/L)  and  low  capacity  the  enzyme  becomes  saturated  after  only  few  drinks. 
Subsequently,  the  acetaldehyde  is  then  oxidized  in  a  nonreversible  reaction  to  acetate  by  the 
mitochondrial isoform of ALDH. Since acetaldehyde is highly toxic, it must be eliminated soon after Int. J. Environ. Res. Public Health 2010, 7                 
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its formation, therefore this enzyme has a very low Km and the elimination of acetaldehyde is very 
efficient  [36].  The  activated  form  of  acetate, acetyl  CoA,  may  be  further  metabolized,  leading  to 
ketone bodies, amino acids, fatty acids and steroids [35]; when it is oxidized in the Krebs cycle, CO2 
and water are formed as the end-products of ethanol oxidation [5]. Both ADH and ALDH utilize the 
cofactor nicotinamide adenine dinucleotide (NAD
+), which is reduced to NADH; as a consequence, 
during ethanol oxidation the ratio NADH/NAD
+ is significantly increased, altering the cellular redox 
state and triggering a number of adverse effects, related to alcohol consumption [32]. 
Figure 1. Oxidative pathways of alcohol metabolism. The enzymes alcohol dehydrogenase 
(ADH),  cytochrome  P450  2E1  (CYP2E1),  and  catalase  all  contribute  to  oxidative 
metabolism of alcohol. ADH, present in the cytosol, converts ethanol to acetaldehyde. This 
reaction involves an intermediate carrier of electrons, nicotinamide adenine dinucleotide 
(NAD
+),  which  is  reduced  by  two  electrons  to  form  NADH.  Catalase,  located  in 
peroxisomes,  requires  hydrogen  peroxide  (H2O2)  to  oxidize  alcohol.  CYP2E1,  present 
predominantly in the cell´ s microsomes  metabolize alcohol to acetaldehyde at elevated 
ethanol concentrations. Acetaldehyde is metabolized mainly by aldehyde dehydrogenase 2 
(ALDH2) in the mitochondria to form acetate and NADH (Adapted from [34]). 
 
In people who are chronic alcohol consumers, a second pathway, the microsomal ethanol-oxidizing 
system (MEOS), which functions in the smooth endoplasmic reticulum of hepatocytes, helps rid the 
body of toxic compounds through cytochrome P450 (CYP2E1), which, like ADH, converts alcohol to 
acetaldehyde [6,7]. This reaction also requires oxygen and reduced NADPH to form NADP and water. 
This enzyme is characterized by a low affinity (Km = 0.5–0.8 g/L) with respect to ADH [36]. As a 
third route of ethanol metabolism, catalase located in the cell bodies called peroxisomes, is capable of 
oxidizing a small amount (2%) of ethanol in the presence of a hydrogen peroxide (H2O2)-generating 
system [35], to form acetaldehyde, without requiring NAD as a cofactor (Figure 1) [37]. Int. J. Environ. Res. Public Health 2010, 7                 
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Acetaldehyde and acetate, produced from the oxidative metabolism of alcohol, contribute to cell 
and tissue damage in various ways. Acetaldehyde has the capacity to bind to proteins such as enzymes, 
microsomal proteins, and microtubules. Formation of protein adducts in hepatocytes impairs protein 
secretion, which has been proposed to play a role in hepatomegaly [35]. It also forms adducts with the 
brain signaling chemical dopamine to form salsolinol, which may contribute to alcohol dependence, 
and with DNA to form carcinogenic DNA adducts such as 1,N2-propanodeoxyguanosine [35]. On the 
other hand, most of the acetate resulting from alcohol metabolism escapes the liver to the blood and is 
eventually metabolized to CO2 in heart, skeletal muscle, and brain cells [35]. Acetate increases blood 
flow into the liver and depresses the central nervous system, as well as affects various metabolic 
processes [35]. 
Besides,  mitochondria  have  an  important  role  in  the  alcohol  metabolism,  and  their  function  is 
affected by alcohol consumption. It has been hypothesized that upon chronic alcohol intake the brain 
starts using acetate rather than glucose as a source of energy [35], and the accumulated acetaldehyde 
exerts  its  toxic  effects  by  inhibiting  mitochondrial  reactions  and  functions.  In  addition,  there  is 
considerable evidence that chronic alcohol exposure enhances the susceptibility of cells to undergo 
apoptosis, therefore is important to understand the role of mitochondria during alcohol consumption 
and metabolism in chronic alcohol consumption. 
2. Effects of Alcohol on Mitochondrial Biomolecules 
A mitochondrion is a membrane-enclosed organelle found in most eukaryotic cells. Mitochondria 
are sometimes described as “cellular power plants” because they generate the majority of the cell’s 
supply of adenosine triphosphate (ATP), which is used as a source of chemical energy. Its importance 
lies in that it contains Krebs cycle enzymes, β-oxidation, oxidative phosphorylation, and components 
of the electron transport chain. The number of mitochondria in a cell varies widely by organism and 
tissue type. The mitochondria play an important role in the alcohol metabolism via the enzyme ALDH; 
this  enzyme  catalyzes  the  conversion  of  acetaldehyde  into  acetate.  When  this  enzyme  reaches  a 
saturation point, the acetaldehyde escapes into the blood stream and leads damage to biomolecules 
such lipids, proteins and nucleic acids which results of the toxic side effects that are associated with 
alcohol consumption. 
There is evidence that ethanol produces alterations in the mitochondrial structure and function of 
several organs, including liver [38], and heart [39], both in laboratory animals and humans [40]. These 
changes affect the mitochondrial function decreasing respiratory rates [41] and ATP levels, and might 
result in increased production of reactive oxygen species (ROS)  [42]. Several enzymatic systems, 
including  the  cytochrome  P450  (CYP2E1),  the  mitochondrial  respiratory  chain  and  the  cytosolic 
enzymes xanthine oxidase and the aldehyde oxidases have been implicated as sources of superoxide 
anion (O2
.–) and H2O2 in parenchyma cells during ethanol intoxication [43]. Numerous studies shows 
that mitochondrial levels of ROS may be increased by chronic alcohol consumption as a consequence 
of increased  mitochondrial  CYP2E1 levels  [44,45] as  well as  a  by-product  of the  matrix enzyme  
α-ketoglutarate dehydrogenase [42]. The CYP2E1 activity increases in alcohol-treated rodents [46] and 
humans not only in alcohol abusers, but also in moderate alcohol consumers [47]. It has a high rate of 
NADPH oxidase activity, which leads to the production of large quantities of O2
– and H2O2 [48]. In Int. J. Environ. Res. Public Health 2010, 7                 
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addition, the ethanol metabolism increases the availability of reducing equivalents (i.e., NADH) to the 
mitochondrion, which results of the redox active semiquinone intermediates within complexes I and III 
to be a more “reduced” state, thereby facilitating the reduction of O2 to O2
– [49]. Also, chronic alcohol 
exposure decrease the activities of all the oxidative phosphorylation complexes, except complex II [50] 
contributing to decreased functioning of the oxidative phosphorylation system and depressed rates of 
ATP synthesis [51]. As well, ethanol has been demonstrated to increase the production of ROS and 
reactive nitrogen species (RNS) and decrease several antioxidant mechanisms in liver [38]. This in 
turn might result in oxidative modification and inactivation of mitochondrial macromolecules, thereby 
contributing to mitochondrial dysfunction and a loss in energy conservation [38]. 
The mitochondrial proteome is exquisitely sensitive to modifications by ROS and RNS and thus 
offers an opportunity to investigate the molecular mechanisms underlying pathobiology from chronic 
alcohol consumption [52]. The oxidation of mitochondrial proteins is a common feature of both acute 
and chronic ethanol exposure [53]. Early studies by Coleman and Cunningham established a key link 
between  the  chronic  alcohol-related  defects  in  complexes  I,  III,  IV,  and  V,  and  losses  in  the  13 
mitochondrial encoded polypeptides and redox centers that comprises the oxidative phosphorylation 
system complexes [54]. Then, proteomic analysis revealed that 40 additional mitochondrial proteins 
had  altered  levels  in  response  to  chronic  alcohol  consumption.  This  includes  several  key  energy 
metabolism enzymes of β-oxidation, the TCA cycle, and amino acid metabolism [55]. On the other 
hand,  nitric  oxide  (NO)  production  is  increased  in  response  to  chronic  alcohol  via  induction  of 
inducible nitric oxide synthase (iNOS) [56]. NO and its metabolite peroxynitrite (ONOO
–) have been 
implicated as key mediators of mitochondrial dysfunction [57]. This ONOO
– can directly or indirectly 
participate  in  reactions  leading  to  inactivation  of  mitochondrial  proteins  via  post-translational 
modifications [52,58]. Also, the identification of proteins with oxidized and/or modified thiol groups 
are critical for elucidating the mitochondrial defects that contribute to alcoholic liver disease [52]. A 
number of reversible and irreversible modifications to cysteine residues are known to occur upon 
interaction of free sulfhydryl groups (-SH) with ROS, RNS; and reactive lipids [52]. As a consequence 
of oxidative modification of thiols others have shown an alcohol-dependent loss of function of the 
mitochondrial low Km ALDH [55]. Additionally, Moon et al. have demonstrated alcohol-dependent 
inactivation of ALDH and several β-oxidation enzymes via oxidation and nitrosation of thiols [59]. 
These findings are consistent with the concept that modification of protein thiols may contribute to 
alcoholic steatosis and mitochondrial dysfunction through inactivation of proteins critical to the energy 
conservation pathways in liver [52]. 
On the other hand, lipid peroxidation has been linked to the impairment of mitochondrial oxidative 
phosphorylation and the appearance of megamitochondria [60]. In patients with alcoholic liver disease 
(ALD) the serum markers of lipid peroxidation, such as conjugated dienes, malondialdehyde (MDA), 
4-hydroxynonenal and F2-isoprostanes are increased [61]. These compounds can form adducts with 
proteins in the areas of fat liver infiltration, focal necrosis and fibrosis [62]. The levels of hydroxyl 
radicals, which exert their cytotoxic effects by causing peroxidation of membrane phospholipids, are 
also increased, increasing membrane permeability plus impairing membrane function [63], leading the 
collapse  of  the  mitochondrial  membrane  potential  and  the  onset  of  mitochondrial  permeability 
transition  (MPT)  [53].  Other  studies  showed  that  lipoperoxidation  increased  the  sensitivity  of  the Int. J. Environ. Res. Public Health 2010, 7                 
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electron transport chain to inhibition by oxidative stress except at the level of complex II [64]. There is 
evidence that oxidative stress affects the mitochondrial DNA (mtDNA).  
In hepatocytes from male Wistar rats, there is a positive correlation between hepatic ATP content 
and the number of single-stranded DNA (ss-DNA)-positive cells. A mitochondrial function, at least in 
part, ATP synthesis was depressed before the damage of mtDNA by chronic ethanol consumption [65].  
Mansouri  et  al.  [66]  found  in  the  liver  tissue  and  white  blood  cells  from  patients  with  ALD  a 
significantly decreased mtDNA copy number and an increased level of mtDNA deletion, similar to the 
data obtained by Tsuchishima et al. [67] who also found an acquired mutation of mtDNA, at least in 
the  encoding  ATPase  region,  that  may  be  reversed  by  stopping  drinking.  In  addition,  
von Wurmb-Schwark et al. [68] investigated mitochondrial mutagenesis in patients with a chronic and 
moderate alcoholic disease, and found a relative amount of 4,977 bp deleted in mtDNA in alcoholics 
compared to controls. 
Bailey [38] showed that there is a decrease in several antioxidant mechanisms in liver caused by 
increased ROS and RNA levels during chronic alcohol exposure. Early studies have shown that a 
decrease in the liver content or reduced GSH is a common feature in ethanol-fed animals as well as in 
patients with alcoholism [43]. Chronic alcohol intake lowers the mitochondrial GSH (mtGSH) [69], 
which makes these organelles more susceptible to oxidative damage, and precedes the development of 
mitochondrial dysfunctions, such as lipid peroxidation [69], and the impairment of ATP synthesis [70]. 
Several investigations using the enteral alcohol model [71] have shown a marked decline in enzymatic 
activity  and  immunoreactive  protein  concentrations  of  liver  Cu,  Zn  superoxide  dismutase  (SOD), 
catalase and GSH peroxidase, suggesting that ethanol might interfere at the post-transcriptional level 
with the synthesis of antioxidant enzymes or might stimulate their intracellular degradation [43]. 
The  damage  accumulated  in  biomolecules  triggered  by  acetaldehyde  exerts  its  toxic  effects  by 
inhibiting the mitochondrial reactions and functions (Figure 2). This compound may injure the electron 
transport chain (ETC) function, leading to production of ROS, which can oxidize the subunits of ETC 
complexes,  leading  injury  over electron transport and  oxidative phosphorylation [72,73], therefore 
decreasing the ATP levels. In addition, the ROS may lead oxidative stress over lipids causing lipid 
peroxidation, which affects the permeability of the outer and/or inner mitochondrial membranes. These 
allows opening of the mitochondrial permeability transition pore (MPTP) and lead to mitochondrial 
permeability  transition  (MPT),  favoring  the  translocation to  the  mitochondria  of  the  pro-apoptotic 
factor Bax that forms a complex with a voltage-dependent anion channel (VDAC). Extensive MPT 
leads to mitochondria swelling as a result of the influx of ions and water, and permits the cytochrome c 
release [74], leading to caspases activation [75] and DNA fragmentation, which are key events for 
induction of programmed cell death or apoptosis [74]. Int. J. Environ. Res. Public Health 2010, 7                 
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Figure  2.  Ethanol  effects  on  mitochondrial  function.  Alcohol  is  metabolized  to 
acetaldehyde  by  the  cytosolic  enzyme  alcohol  dehydrogenase  (ADH).  Mitochondrial 
aldehyde dehydrogenase 2 (ALDH2) converts acetaldehyde to acetate. When this enzyme 
is malfunctioning, acetaldehyde increases and damages the electron transport complexes 
(CI-CIV) leading over production of reactive oxygen species (ROS), affecting electron 
transport  chain  (ETC)  and  oxidative  phosphorylation  disturbing  ATP  synthesis.  Also, 
oxidative  stress  affects  the  permeability  of  the  outer/inner  mitochondrial  membranes 
(OMM/IMM) promoting opening of the permeability transition pore (PTP) favoring the 
translocation  of  the  pro-apoptotic  factor  bax,  which  forms  a  complex  with  
voltage-dependent anion channel (VDAV). When the mitochondrial permeability transition 
is extensive, promotes the mitochondrial swelling and permits the cytochrome c release 
(Cyt c), caspase activation and DNA fragmentation, leading the programmed cell death or 
apoptosis.  MM,  mitochondrial  matrix;  ∆Ψm,  mitochondrial  membrane  potential.  IMS, 
intramitochondrial space; Apaf-1, Apoptotic protease activating factor-1; ATP, adenosine 
triphosphate; ADP, adenosine diphosphate. 
 
3. Alcohol Effects on the Heart 
Chronic alcohol abuse has been established as a major cause of cardiomyopathy in humans [76]. 
The  heart  becomes  enlarged  and  has  flaccid  muscle  tone,  presents  scattered  areas  of  muscle 
degeneration,  fibrosis,  intracellular  edema,  lymphocytic  infiltration  and  numerous  fat  droplets  are Int. J. Environ. Res. Public Health 2010, 7                 
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observed in muscle-cell cytoplasm. These changes may lead the loss of cells by either necrosis or 
apoptosis  as  a  plausible  mechanism  for  decrease  in  contractile  function  [77].  In  addition,  ethanol 
causes changes in the spatial reorganization of mitochondria: intermitochondrial contacts disappear, 
and the mitochondrial population regroups into separate clusters uniformly distributed over the space 
of a muscle cell. Subsequently, megamitochondria and septate mitochondria appear. These changes 
may be considered a sign of impairments of myocardial functioning. Data of animal experiments show 
a decrease in the rates of respiration and oxidative phosphorylation [78]. In baboons the cytochrome c 
oxidase concentration and activity decreased two-fold, while in rats causes a decrease of oxidative 
phosphorylation  efficiency  and  weakening  of  the  factor  F1  connection  with  mitochondrial  
membrane [79].  
Alcoholic  beverages  contain  more  than  200  compounds  with  different  antioxidant  activities  to 
polyphenols,  including  quercetin,  catechin,  tannic  acids  [80],  and  resveratrol,  among  others  [81]. 
Resveratrol  is  a  polyphenolic  phytoalexin  (trans-3,4’,5-trihydroxystilbene)  present  in  purple  grape 
juice, peanuts, and red wine [35,82] and has ability to prevent or slow the progression of a variety of 
pathologies [83]. It also possesses many health benefits that include cardioprotection [84]. It may 
reduce  the  incidence of coronary heart  disease by its  antioxidant [85] and  anti-inflammatory  [86] 
activities,  preconditioning  against  ischemic  injury  [87],  reduced  ischemia-reperfusion  injury  and 
infarction [88], attenuated hypertrophic response [89], enhanced peri-infarct neovascularization [90], 
and antiarrhytmic efficacy [91], inhibit cardiac fibroblast proliferation and differentiation in vitro [92]. 
Resveratrol can retard progression of atherosclerosis. In apolipoprotein E-deficient mice, resveratrol 
reduces the susceptibility of LDL to oxidation and aggregation [93], while in vascular smooth muscle 
cells  inhibited  the  platelet-derived  growth  factor  beta  receptor  (PDGF)  that  is  crucial  on  the 
development of atherosclerosis [94]. In addition, it interferes with angiotensin II and epidermal growth 
factor signaling in vascular smooth muscle cells, which may be a long-term mechanism for inhibition 
of  atherosclerosis  [95].  In  patients  with  coronary  artery  disease  resveratrol  decreased  arterial  
stiffness  [96].  The  supplementation  of  this  compound  controls  the  high  cholesterol  diet-induced 
myocardial complications such as myocardial and aortic damage in mice [97] and increases infarct size 
in rats [98], by regulating signal transduction pathways that leads to angiogenesis and cardioprotection 
in  the  hypercholesterolemic  myocardium  [99].  The  enhanced  neovascularization  observed  in  the 
infarcted rat myocardium [100] may be due to its ability to modulate certain signal pathways of cell 
proliferation and survival [83]. 
4. Alcohol Effects on the Stomach 
Alcohol is absorbed rapidly through the bloodstream from the stomach and intestinal tract. High 
concentrations of ethanol induce vascular endothelium injury of the gastric mucosa, which became 
edematous, and congestive, present point and scattered bleeding lesions, focal hemorrhage, necrosis, 
and giant and deep ulcers were visible [101]. Principal cells and parietal cells become swollen and 
diminished  [101].  These  cells  are  rich  in  mitochondria  [102],  which  provide  energy  by  oxidative 
phosphorylation, which is critical for maintaining the proper morphology and function of the gastric 
mucosa.  The  mitochondrion  is  an  easily  injured  organelle,  and  mtDNA  is  the  major  target  of  
ethanol-associated intracellular oxidative stress associated [103]. There are evidences that during the Int. J. Environ. Res. Public Health 2010, 7                 
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expression of mtDNA, the subunits 6 and 8 mRNA of ATPase decreased in ethanol-induced acute 
injury [101], and the lack of ATP may lead to metabolic acidosis, cellular edema, intracellular calcium 
overload, and further damage to gastric mucosa cells [104]. 
Alcohol exposure affects the mitochondrial structure which became swollen and disaggregated, and 
the cristae were dissolved and disappeared [101], giving rise to megamitochondria [105], which have 
oxygen consumption, ATP synthesis, and ROS-formation rates lower than those of controls. Therefore, 
it was proposed that enlargement of the mitochondria is an adaptive process by which cells attempt to 
decrease the intracellular amount of ROS when they are subjected to oxidative stress [106]. Gastric 
mucosa  is  rich  in  protein  sulfhydryl  groups,  which  may  be  the  target  of  ROS.  Oxidized  protein 
sulfhydryl  groups  lead  to  protein  denaturation  or  enzyme  inactivation  and  receptor  damage  or 
modification of the cell membrane, thus contributing to mucosal injury [107]. 
5. Alcohol Effects on the Liver 
Alcoholic liver disease is damage to the liver due to alcohol abuse and usually occurs after years of 
excessive  drinking.  Changes  in  the  liver  include  steatosis,  steatohepatitits  to  fibrosis  and  
cirrhosis  [108,109].  Moreover,  chronic  alcohol  consumption  is  an  established  risk  factor  for  the 
development of hepatocellular carcinoma in patients with liver cirrhosis [110]. 
In early stages of the ALD, the alcoholic steatosis is the initial pathology characterized by the 
accumulation of lipids in the liver. The progression to alcoholic steatohepatitis represents the key step 
in the development of ALD, where hepatic stellate cells are activated and recognized as fibrogenic 
cells and lead to deposition of collagen [111]. Also, activated Kupffer cells secrete pro-inflammatory 
cytokines,  linking  apoptosis  in  the  liver  to  inflammation  [112].  When  ALD  is  established,  an 
accumulation  of  reducing  equivalents  in  the  cytosol  and  the  rates  of  fatty  acids  biosynthesis  and 
subsequent esterification into triglycerols are increased [113]. It is also possible to observe massive 
hepatocyte apoptosis, which induces progressive fibrosis, and could result in liver failure, cirrhosis, 
and hepatocellular carcinoma [111]. 
Liver  injury  mediated  by  alcohol  involves  both  liver  parenchymal  and  nonparenchymal  cells, 
including resident and recruited immune cells that contribute to liver damage and inflammation [114]. 
Biopsies from patients with ALD showed partial villous atrophy, increase in lamina propia infiltrate, 
and  intraepithelial  lymphocytes.  Ultrastructural  evaluation  revealed  changes  such  as  widened 
intercellular junction, distorted microvilli, increased rough endoplasmic reticulum, and increased and 
dilated mitochondria [115]. Chronic alcohol administration favors the formation of megamitochondria, 
due  to  increasing  mitochondrial  membrane  permeability  and  decreasing  mitochondrial  membrane 
potential [116] and diminished activity of mitochondrial respiratory chain complexes [117]. 
Mitochondrial and cellular oxidative stress in chronic alcoholism appears to be the major cause of 
augmented  mitochondrial  production  of  superoxide  anion  (O2
.–)  at  complexes  I  and  III,  and 
consequently  the  production  of  H2O2  and  other  ROS,  triggered  by  NADH  overproduction. 
Mitochondrial oxidative stress renders hepatocytes susceptible to ethanol- or acetaldehyde-induced 
mitochondrial membrane permeability transition (MMPT), apoptosis in chronic alcoholism and biliary 
cirrhosis [118]. Through phosphorylation/dephosphorylation of Bcl-2 proteins, chronic ethanol may Int. J. Environ. Res. Public Health 2010, 7                 
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control  the  sensitivity  of  mitochondria  toward  a  variety  of  membrane  permeabilization-inducing 
factors [119]. 
6. Alcohol Effects on the Nervous System 
For a long time the effect of alcohol was thought to be a generalized depression of neural activity 
causing global impairment of cognitive, psychological, and behavioral domains [120]. Recently, it has 
been shown that ethanol can alter mentation in a variety of ways affecting many neurotransmitter 
systems [121]. Early symptoms of acute intoxication are euphoria and disinhibition, which progress to 
stupor and respiratory depression [122]. Abrupt abstinence after prolonged or binge drinking can result 
in tremors, hallucinations (visual, auditory, or tactile), seizures, or delirium tremens, with severely 
constricted attentiveness, fluctuating levels of alertness, agitation, and autonomic instability [123]. It is 
possible,  moreover,  that  repeated  binges  and  withdrawals  cause  permanent  neuronal  damage 
contributing to more lasting neurological disorders, including dementia [124]. 
Animal  experiments  have  demonstrated  that  bouts  of  binge  drinking  can  produce  necrotic 
neurodegeneration in brain areas most closely associated with the hippocampus [125]. Acute ethanol 
administration  produces  dose-dependent  impairments  in  spatial  learning,  and  decreases  the  spatial 
specificity  of  hippocampus  place  cells  [126].  Additionally,  adult  neurogenesis  within  the 
hippocampus’  dentate  gyrus  is  selectively  impaired  in  a  rat  model  of  alcoholism.  This  impaired 
neurogenesis may be a mechanism that mediates the cognitive deficits observed in alcoholism, thus 
agree with the hypothesis that alcohol interferes with learning processes and memory recall [127]. 
To date, the exact mechanism of action of this compound is unknown, but it has been observed that 
it acts on gamma amino butyric acid (GABA) receptors by enhancing the effects of GABA, producing 
an  anxiolytic  effect.  It  also  blocks  the  binding  of  glutamate  to  its  receptor,  N-methyl-D-aspartate 
(NMDA), and reversibly reduces sodium transport in neurotransmission [128] and voltage-dependent 
calcium channels blocking, thus inhibiting the release of neurotransmitters [129], such as serotonin, 
acetylcholine, dopamine, noradrenaline, endorphin, encephalin, and neuropeptide Y [128].  
Recent investigations have suggested that ethanol influences on special transmitter systems and 
mechanisms  of  formation  of  morphine-analogous  condensation  products  are  presented  in  
addiction [130]. During development of alcoholism there is progressive accumulation of acetaldehyde 
and a parallel increase of dopamine concentration in blood creating conditions for the condensation of 
acetaldehyde with dopamine [131] producing tetrahydropapaveroline [132], which is an intermediate 
in the biosynthesis of morphine [133]. Also, biogenic amines may react with acetaldehyde to form 
isoquinoline  or  carboline  compounds,  which  may  enter  neural  stores  and  displace  the  natural 
neurotransmitter, thus they can act as false neurotransmitters [132]. These results suggest that these 
compounds  may  be  responsible  for  development  of  alcohol  addiction.  In  addition,  as  products  of 
alcohol  metabolism  also  generates  ROS  and  nitric  oxide  (NO)  via  induction  of  NADPH/xanthine 
oxidase and nitric oxide synthase (NOS) in human neurons contributing to oxidative and nitrosative 
stress [134]. 
Brain mitochondria appear to be the principal targets of the oxidative stress generated by ethanol 
intoxication and withdrawal. This stress causes extensive degradation and depletion of brain mtDNA 
in mice [135] and decreases cytochrome c oxidase (COX) activity in a variety of neurodegenerative Int. J. Environ. Res. Public Health 2010, 7                 
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illnesses,  such  Parkinson  disease  and  Alzheimer  disease  (AD).  Upon  removal  of  chronic  ethanol, 
excessive glutamate-induced neuronal excitation, increases intracellular concentrations of Ca
2+ and 
ROS, factors  that provoke  PTP opening, allowing for non-selective passage  of solutes and water, 
leading  mitochondrial  swelling  and  possible  rupture  and  decreased  efficiency  of  mitochondrial 
respiration [136,137]. In AD, epidemiological studies have indicated that alcohol consumption plays a 
role in the development of the disease, due to enhances beta-amyloid (Abeta)-induced neuronal cell 
death by increasing ROS and mitochondrial dysfunction [138]. 
7. Alcohol and Prenatal Effects 
Due to its soluble nature, alcohol does not bind to any tissue nor is it bound to plasma proteins, but 
can cross the blood brain barrier and placenta [139]. Prenatal exposure to ethanol during development 
induces a wide spectrum of adverse effects in offspring; the most extreme of which is fetal alcohol 
syndrome  (FAS),  a  condition  characterized  by  microcephaly,  neurologic  abnormalities,  facial 
dysmorphology, and pre- and post-natal growth retardation [139]. Neuropathologic abnormalities in 
FAS include neuronal-glial heterotopias, cerebellar dysplasia, and agenesis of the corpus callosum, 
hydrocephalus, and microcephaly [140]. These lesions are indicative of aberrant migration, decreased 
proliferation,  and  the  death  of  neuronal  cells.  Pregnant  women  are  well  advised  to  abstain  from 
drinking ethanol, due to that serotonin (a trophic factor for brain development) levels are significantly 
decreased  in  a  ethanol-exposed  fetus [141]  and  reduces  the  number  of  developing  
serotonin  (5-HT)-containing  neurons  by  increasing  apoptosis.  Also,  serotonin  reduces  several 
prosurvival proteins, such as Bcl-2 [142]. Hence, alcohol may affect the growth of the fetus's forebrain 
through its effect on 5-HT signaling [143]. 
It has been postulated that neuronal alterations found in FAS could be due to some initial damage 
during development on astrocytes, which are more susceptible to the toxic effect of ethanol during 
proliferation than during differentiation. The number of mitochondria was lower and they were more  
elongated [144]. Electron microscopic studies on fetal rat hepatocytes illustrated a slight disruption of 
mitochondrial  structure  such  as  enlargement  of  mitochondria  and  dilation  of  cristae  [145].  This 
disruption was accompanied by mitochondrial swelling, altered mitochondrial  membrane potential, 
decrease in succinate dehydrogenase activity, and decrease in cellular ATP levels [145]. There are 
evidences  that  chronic  ethanol  intake  during  pregnancy  in  rats  increased  fetal  liver  aldehyde 
dehydrogenase in the mitochondrial fraction, in which the activity was 10-fold higher than in the 
placenta mitochondrial fraction [146]. 
8. Alcoholism Therapeutics at the Mitochondrial Level  
It is important to understand the basic mechanisms of alcohol metabolism by the mitochondria, as 
well as the effects of alcohol on their functioning in order to develop new therapies for the treatment of 
alcohol addiction. Currently, among techniques used to prevent alcohol addiction-associated cellular 
injury, it has been employed the compound curcumin, a polyphenolic phytochemical that is extracted 
from  the  ryzomes  of  Curcuma  longa,  a  perennial  herb  distributed  throughout  the  tropical  and 
subtropical regions of the world and commonly used in India as a spice and medical agent. Curcumin 
is known to protect the liver, pancreas, and nervous system from toxic effects caused by alcohol Int. J. Environ. Res. Public Health 2010, 7                 
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consumption [147]. Numerous studies highlighted that curcumin is a potent scavenger of a variety of 
ROS, such as superoxide anion, hydroxyl radicals, and nitric oxide [147]. Among of the antioxidant 
properties  of  curcumin  attributed  include  inhibition  of  the  oxidative  damage  of  proteins  and  the 
peroxidation of membrane lipids in rat liver mitochondria [148], the H-atom abstraction from the 
phenolic  OH  groups  present  in  its  molecular  structure  [149],  and  chelating  of  metal  ions  such  
as iron [150]. 
The well documented cardioprotective effects of moderate alcohol consumption in animal models 
and in humans [149] are due to increased blood pressure and also those antioxidants properties, which 
can prevent oxidative stress. Resveratrol possesses diverse biochemical and physiological actions that 
include the ability to protect brain, kidney, and heart from ischemic injury [150]. It has estrogenic, 
antiplatelet, and anti-inflammatory properties [151]. The cardioprotective effects of resveratrol have 
been  attributed  to  their  antioxidant  and  anti-inflammatory  properties  [152,153].  This  compound 
inhibits angiotensin II (A-II)-induced cardiomyocyte hypertrophy, because it inhibits production of 
ROS [154] and reduces 4-hydroxy-2-nonenal (HNE) levels in hearts from spontaneously hypertensive 
rats  [155]  maybe  by  increasing  plasma  antioxidant  capacity  [156]  and  over  expression  of 
mitochondrial superoxide dismutase, which improved respiration and normalized mass mitochondria 
in diabetic mice [99]. In addition, the beneficial role of resveratrol may be due also to increasing 
mitochondrial number as observed in obese mice [157]. 
Piceatannol  (3,3’,4’,5-tetrahydroxystilbene,  astinginin)  is  a  resveratrol  derivative  with  higher 
antioxidant  capacity,  found  in  the  seeds  of  Euphorbia  lagascae  [157].  Piceatannol  possesses  an 
additional  hydroxyl  group  than  resveratrol  (3,5,4’-trihydroxystilbene)  and  exerts  higher  radical 
scavenging activity which was considered to contribute to the cardioprotective and antiarrhythmic 
effects  in  ischaemic-reperfused  rat  heart  [158,159].  Another  potential  compound  in  mitochondrial 
therapeutics is the structural GABA analogue citrocard (phenibut citrate) that prevents the damaging 
effect of alcohol, which was observed from increased indexes of oxidative phosphorylation in treated 
animals [78]. 
Ethanol-related  mitochondrial  dysfunction  has  been  considered  one  of  the  major  mechanisms 
contributing to lipid metabolism changes in the liver leading to steatosis [160]. Treatment of steatosis 
with IL-6 induces expression of anti-apoptotic Bcl-xL protein in primary mouse hepatocytes [161], 
which protects against ethanol-induced oxidative stress and mitochondrial injury in the liver [161]. 
Acetaldehyde is a reactive and toxic metabolite of ethanol that could affect drinking behavior and 
susceptibility  to  alcoholism.  Acetaldehyde  is  converted  into  acetate  by  cytosolic  or  mitochondrial 
aldehyde dehydrogenase (ALDH). Mitochondrial ALDH (ALDH2) might be responsible for 60% of 
acetaldehyde metabolism. There is evidence that the ALDH2*2 gene encoding the inactive variant of 
ALDH2  protects  nearly  all  carriers  of  this  gene  from  alcoholism.  Inhibition  of  ALDH2  has  thus 
become a possible strategy to treat alcoholism [162].  
Other agents that have received considerable attention in recent years as a potential therapeutic 
against alcohol-induced organs injury are betaine and S-adenosyl-L-methionine, which have beneficial 
effects on mitochondrial functions. Betaine, also known as trimethylglycine, is a methyl donor, which 
can replace folate or S-ademethionine in the human body [163], where it participates in the methionine 
recycling,  and  phosphatidylcholine  synthesis  [164].  Many  studies  have  indicated  that  betaine  can 
prevent the alcohol-induced injury and improve the cellular function [165] through the inhibition of Int. J. Environ. Res. Public Health 2010, 7                 
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inflammatory  factor,  the  decrease  of  lipid  peroxidation,  and  prevents  apoptosis  [166].  The  other 
compound, S-adenosyl-L-methionine (SAM), present in all living cells, is synthesized from methionine 
and ATP [167] by the enzyme methionine adenosyltransferase (MAT) [168]. Its biochemical functions 
are: (1) a donor of methyl groups; (2) a sulfur-containing metabolite for the transsulfuration pathway 
that  leads  to  the  synthesis  of  cysteine  and  glutathione;  and  (3)  a  precursor  molecule  for  the 
aminopropylation pathway that provokes the synthesis of polyamines [168]. SAM plays an important 
role in regulating mitochondrial function [169], due to the fact that SAM prevents alcohol-dependent 
mitochondrial  dysfunction  via  the  preservation  of  mitochondrial  respiration,  attenuation  of 
mitochondrial O2
– production, and maintenance of the integrity of the mtDNA [170]. 
9. Concluding Remarks 
The metabolism of ethanol is closely linked with stimulation of reactive oxygen species generation 
and  oxidative  stress.  The  ability  of  alcohol  to  promote  oxidative  stress  and  the  role  of  ROS  in  
alcohol-induced tissue injury clearly are important areas of research in the alcohol field, particularly 
because  such  information  may  be  of  major  therapeutic  significance  in  the  development  of  more 
effective and selective new medications capable of blocking the actions of ROS and consequently the 
toxic  effects  of  alcohol.  This  knowledge  will  clearly  advance  the  design  and  testing  of  novel 
mitochondria-specific therapeutics on the treatment of diseases in alcoholic patients. The identification 
of  possible  biomarkers  of  susceptibility  will  represent  the  main  goal  in  the  near  future  and  will 
contribute to the implementation of adequate prevention strategies, to the development of effective 
diagnostic test strategies, to detect higher risk drinking behavior and early indicators of tissue damage. 
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